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The Raf/MEK/extracellular signal-regulated kinase
(ERK) pathway participates in many processes altered
in development and progression of cancer in human
beings such as proliferation, transformation, differ-
entiation, and apoptosis. Kinase suppressor of Ras 1
(KSR1) can interact with various kinases of the Raf/
MEK/extracellular signal-regulated kinase pathway to
enhance its activation. The role of KSR1 in endome-
trial carcinogenesis was investigated. cDNA and tissue
microarrays demonstrated that expression of KSR1
was up-regulated in endometrial carcinoma. Further-
more, inhibition of KSR1 expression by specific small
hairpin RNA resulted in reduction of both prolifera-
tion and anchorage-independent cell growth proper-
ties of endometrial cancer cells. Because inhibition of
apoptosis has a pivotal role in endometrial carcino-
genesis, the effects of KSR1 in regulation of tumor
necrosis factor–related apoptosis-inducing ligand
(TRAIL)–induced apoptosis were investigated. KSR1
knock-down sensitized resistant endometrial cell
lines to both TRAIL- and Fas-induced apoptosis. Sen-
sitization to TRAIL and agonistic anti-Fas antibodywas caused by down-regulation of FLIP (FLICE-inhib-
itory protein). Also investigated was the molecular
mechanism by which KSR1 regulates FLIP protein lev-
els. It was demonstrated that KSR1 small hairpin RNA
did not affect FLIP transcription or degradation.
Rather, FLIP down-regulation was caused by Fas-asso-
ciated death domain protein–dependent inhibition of
FLIP translation triggered after TRAIL stimulation in
KSR1-silenced cells. Re-expression of heterologous
KSR1 in cells with down-regulated endogenous KSR1
restored FLIP protein levels and TRAIL resistance. In
conclusion, KSR1 regulates endometrial sensitivity to
TRAIL by regulating FLIP levels. (Am J Pathol 2011, 178:
1529–1543; DOI: 10.1016/j.ajpath.2010.12.041)
The Raf/MEK/extracellular signal-regulated kinase (ERK)
pathway participates in many processes altered in devel-
opment and progression of cancer in human beings such
as proliferation, transformation, differentiation, and apop-
tosis.1 Constitutive or enhanced activation of ERK signal-
ing is a common downstream event in many types of
malignant diseases.
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a scaffold protein that interacts and regulates the inten-
sity and duration of mitogen-activated protein kinase
(MAPK) pathway activation.2 KSR1 was first identified as
a suppressor of Ras-induced tumor phenotype in Caeno-
rhabditis elegans and Drosophila melanogaster genetic
screens.3–5 KSR1 can interact with various kinases of the
Raf/MEK/ERK signaling pathway to enhance its activa-
tion.6–8 Strong evidence of KSR1 scaffolding function
was provided in experiments in which overexpression of
KSR1 in deficient mouse embryonic fibroblasts resulted
in maximal assembly of the Raf-1/MEK/ERK/MAPK com-
plex and optimal ERK/MAPK signaling.9 KSR1 contains a
kinase domain in which the lysine typical of the ATP
binding site of other serine/threonine kinases is substi-
tuted by an arginine. Whether KSR1 contains intrinsic
kinase activity is controversial.10
KSR1 is critical for Ras-induced transformation by active
forms of Ras both in vitro9,11,12 and in vivo.13 Thus, KSR1 is
a suitable target to block Ras-induced tumorigenesis.14
Ras/Raf/MEK/ERK signaling is involved in regulation of
apoptotic cell death triggered by antineoplastic drugs.15
KSR1 regulation of Ras/Raf/MEK/ERK has also been in-
volved in modulation of apoptotic response to death recep-
tors. Colonic epithelial cells from KSR1-deficient mice are
more sensitive to tumor necrosis factor- than are wild-type
cells,16,17 which suggests that KSR1 may participate in
control of apoptosis triggered by death receptors.
It has been previously demonstrated that endometrial
cancer cells (ECCs) exhibit resistance to tumor necrosis
factor family members such as Fas ligand and tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL).18,19 TRAIL
is capable of inducing apoptosis in tumor cells while spar-
ing normal cells.20,21 Thus, TRAIL is a promising therapeutic
agent against cancer, and is currently under clinical tri-
als.22,23 However, there is growing evidence that some tu-
mor populations are resistant to apoptosis triggered by
TRAIL, which makes the intracellular signaling pathways
that modulate apoptotic responses to TRAIL an important
unresolved issue.
Binding of TRAIL to its functional receptors TRAILR1(DR4)
and TRAILR2(DR5) initiate an intracellular response.24–26
Both TRAIL and Fas ligand have been reported to trigger
similar intracellular signaling pathways, and their engage-
ment to TRAIL and Fas receptors leads to formation of a
death-inducing signaling complex that is composed primar-
ily by the TRAIL/Fas receptor, the adaptor protein FADD
(Fas-associated death domain), and the inactive proform of
caspase 8. On formation of the death-inducing signaling
complex, procaspase 8 is processed into its active form,
caspase 8, through autoproteolytic cleavage, which initiates
intracellular apoptotic signaling.27–29 One of the critical reg-
ulators of apoptosis triggered by Fas ligand and TRAIL is
the FLICE (FADD-like interleukin-1–converting enzyme)–
inhibitory protein (FLIP).30,31 It has been previously reported
that high levels of FLIP found in ECCs have a pivotal role in
mediating resistance to TRAIL-induced apoptosis.18 Intra-
cellular FLIP protein levels should be tightly regulated. Such
regulation can be achieved by regulating FLIP transcription,
protein translation, or its degradation via the ubiquitin-pro-
teasome system.Expression of KSR1 is increased in endometrial carci-
noma, which suggests a possible role in endometrial
carcinogenesis. Inhibition of KSR1 expression by lentivi-
ral-delivered small hairpin RNA (shRNA) in ECCs resulted
in marked reduction of both proliferation and anchorage-
independent cell growth properties of ECCs. Because
suppression of apoptosis is an important step in endo-
metrial carcinogenesis, the effects of KSR1 inhibition on
apoptotic response of ECCs was studied. Inhibition of
KSR1 expression sensitized resistant ECC lines to both
TRAIL- and Fas-induced apoptosis via a mechanism de-
pendent on down-regulation of FLIP. Also assessed were
the molecular mechanisms underlying such FLIP down-
regulation. KSR1 shRNA blocks FLIP translation through
regulation of TRAIL-induced phosphorylation of the eu-
karyotic initiation factor 4E (eIF4E), which suggests inhi-
bition of FLIP protein translation.
Materials and Methods
Reagents, Antibodies, and Plasmids
MTT (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyl tetrazo-
lium bromide) assay, cycloheximide, and monoclonal an-
tibody to tubulin and Anti-FLAG M2 were obtained from
Sigma-Aldrich Corp. (St Louis, MO). Caspase inhibitor
BAF, proteasome inhibitors MG-132 and ALLN, antibody
to caspase 8, and recombinant TRAIL were from Calbi-
ochem (La Jolla, CA). Antibodies to caspase 9 and
cleaved caspase 3 were obtained fromCell Signaling Tech-
nology, Inc. (Beverly, MA). Bortezomib (Millennium Pharma-
ceuticals, Cambridge, MA) was obtained from the Depart-
ment of Pharmacy (Hospital Arnau de Vilanova, Lleida,
Spain). Monoclonal antibodies to FLIP (NF6) and Fas ago-
nistic antibody (CH11) were purchased from Alexis Corp.
(Lausen, Switzerland). Antibodies to ITCH and FADD were
from BD Biosciences (Franklin Lakes, NJ). Antibodies to
KSR1 (sc-25416 for immunohistochemistry and sc-9317 for
Western blot analysis) and ubiquitin were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Anti-phospho-eIF4E
serine 209 was from Millipore Corp. (Bedford, MA). Perox-
idase-conjugated anti-mouse, anti-rat, and anti-rabbit anti-
bodies were from Jackson ImmunoResearch Laboratories,
Inc. (West Grove, PA).
Lentiviral vector containing FLAG-tagged mouse FLIP
cDNA was a gift from Dr. Joan Comella (Universitat Au-
tònoma de Barcelona, Barcelona, Spain). FLAG-tagged
pcDNA3-KSR1 has been previously described.11
Collection of Tissue Samples for cDNA Array
Studies
For cDNA studies, two independent series of samples
were used. The first series (series 1) was used for cDNA
hybridization. Series 1 contained 24 ECCs that had been
previously characterized pathologically and molecu-
larly,32 and eight normal endometrial samples including
four each in the late proliferative phase (histologic dating,
10 to 14 days) and early secretory phase (histologic
dating, 15 to 19 days). In brief, the series included 10
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tumors were classified as stage I, and the remainder as
stages II to IV. Normal cycling endometria were obtained
from patients ranging in age from 26 to 45 years who
were undergoing hysterectomy for treatment of small in-
tramural leiomyomas. Samples were obtained from the
mid-fundus. All women had a clinical history of normal
cycles [mean (SD), 28 (2) days], and none had received
hormone therapy in the previous year. Endometria were
dated according to morphologic criteria, and in all pa-
tients the structure of the endometrium was normal and
correlated well with the days of the clinical cycle. Sec-
tions of frozen samples were split for RNA isolation and
confirmatory histology via H&E staining. The study was
approved by the ethics committee, and specific informed
consent was obtained from all patients.
The second series (series 2) was used to cross-vali-
date data obtained from cDNA arrays. In series 2, mRNA
data were obtained from eight normal endometria (four
each in the proliferative and secretory phases) and 26
ECCs comprising 17 grade 1, six grade 2, and three
grade 3 tumors. Twenty-four tumors were classified as
stage I, two as stage II, and one as stage III. The use of
two independent series in cDNA studies provided an
independent validation of cDNA array data.
RNA Extraction, Probe Synthesis, Hybridization
on cDNA Arrays, and Data Analysis
Procedures were performed as previously reported.32 In
brief, total RNA was isolated using TRIZOL reagent (Life
Technologies, Inc., Gaithersburg, MD). Three milligrams
of total RNA and T7-(deoxythymidine)-24 oligo primer
were used to synthesize the double-strand cDNA using
the Superscript Choice System (Life Technologies, Inc.).
In vitro transcription was performed using Megascript T7
(Ambion, Inc., Austin, TX). Three microliters of antisense
RNA was used to generate fluorescence cDNA by tran-
scriptional synthesis using the SuperScript enzyme pro-
tocol (Life Technologies, Inc.). All endometrial samples
were labeled with Cy5-deoxyuridine triphosphate fluoro-
chrome (Amersham Biosciences AB, Uppsala, Sweden),
and the reference sample (Universal Human Reference
RNA; Stratagene Corp., La Jolla, CA) was labeled with
Cy3-deoxyuridine triphosphate fluorochrome (Amersham
Biosciences AB) as previously described.32 The cDNA
array chips used contained 9726 clones corresponding
to 6386 different genes. The chips included 2489 clones
that were printed in duplicate to assess reproducibility
[Bioinformatics Unit, Centro Nacional de Investigaciones
Oncológicas (CNIO), Madrid, Spain].
After hybridization, slides were scanned (ScanArray
5000 XL scanner; GSI Lumonics, Inc., Kanata, ON, Can-
ada) at wavelengths of 635 and 532 nm for Cy5 and Cy3
dyes, respectively, to obtain 10-m resolution images,
which were quantified using the GenePix Pro 6.0 program
(Axon Instruments, Inc., Union City, CA). Fluorescence
intensity measurements from each array element were
compared with the median of the local background in
each channel. Elements with values less than this medianwere excluded. In addition, spots smaller than 25 m
were manually deleted. The expression ratios of the du-
plicated spots on the array were averaged. For statistical
analysis, genes were selected in which expression dif-
fered by a factor of at least twofold with respect to the
reference pool in a minimum of 10% of the samples.
To identify the set of genes that were differentially ex-
pressed in ECCs and normal endometria, the Welch t-test
was used, which does not require equal within-group vari-
ance. To avert an excessive number of false-positive re-
sults, the step-down maxT method was used. Because the
sample size was small, the adjusted P values were obtained
from 50,000 random permutations. Statistical comparison
wasperformedusing thePomelo II program (http://pomelo2.
bioinfo.cnio.es). The SOTA and TreeView programs (Bioin-
formatics Unit, CNIO) were used for clustering analysis,
assuming Euclidean distances between genes.
Semiquantitative RT-PCR and Real-Time PCR
The expression of KSR1 in ECCs and normal endome-
trium was evaluated using semiquantitative RT-PCR per-
formed using the Superscript II system for reverse tran-
scription (Life Technologies, Inc.), beginning with 0.5 g
total RNA and random primers in a 20-L reaction vol-
ume. Reverse transcription product and 0.4 to 1.0 g
oligonucleotide were heated at 95°C for 5 minutes, fol-
lowed by 30 cycles of PCR amplification: 94°C denatur-
ing for 1 minute, 55° to 58°C annealing for 1 minute, and
72°C extension for 1 minute, followed by final extension at
72°C for 10 minutes. All reactions included two pairs of
primers, one corresponding to GADPH (glyceraldehyde-3-
phosphate dehydrogenase), which served as a reference
control gene, and the other for the gene being tested.
Primer sequences were as follows: KSR1 F, 5=-GCAC-
TCGTTTGTGAGGGA-3=, and R, 5=-ACAGCCCGAAGTCT-
GTGA-3=. PCR products were visualized on 3% agarose
gels stained with ethidium bromide. Images were captured
and analyzed using the Quantity One 4.1.1 analyzer and
software (Gel Doc 2000, Bio-Rad Laboratories, Inc., Hercu-
les, CA). Statistical comparison (t-test) was performed using
a commercially available software package (SPSS for Win-
dows, version 10.1; SPSS, Inc., Chicago, IL).
FLIP quantitative real-time PCR was performed as previ-
ously described.33 FLIP and -glucuronidase were ob-
tained (Assay-on-Demand Gene Expression Products ABI
P/N 4331182:Hs00236002_m1 and ABI P/N 4326320E; Ap-
plied Biosystems, Inc., Foster City, CA).
Tissue Microarrays and Immunohistochemistry
Two tissue microarrays (TMAs) were constructed and
processed as previously described34 using tissues from
the surgical pathology files from Hospital Universitari Ar-
nau de Vilanova de Lleida (Lleida, Spain) and Hospital de
Sant Pau (Barcelona, Spain). The first TMA was con-
structed from 80 paraffin-embedded samples of normal
endometrium in different phases of the menstrual cycle:
20 proliferative, 50 secretory, and 10 menstrual. The sec-
ond TMA was constructed from 157 endometrial cancers
including 47 grade 1, 58 grade 2, and 26 grade 3 ECCs, 15
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mixed müllerian malignant tumors. One hundred eight tu-
mors were classified as stage I, 15 were stage II, 22 were
stage III, and one was stage IV. Staging information was
incomplete in 11 cases. Ninety-five tumors had been pre-
viously evaluated for common alterations of endometrial
carcinoma including microsatellite instability and mutations
in KRAS, CTNNB-1, or PTEN. A tissue array device
(Beecher Instruments, Silver Spring, MD) was used. Two
selected cylinders (0.6 mm in largest diameter) from two
different areas were included in each case. Control normal
tissues from the same endometrial carcinoma specimens
were also included. Immunohistochemistry was performed
using a KSR1 antibody (SC-25416; Santa Cruz Biotechnol-
ogy, Inc.; 1:400 dilution), and the reaction was visualized
using the EnVision Detection Kit (DAKO Corp., Carpinteria,
CA) using diaminobenzidine chromogen as a substrate.
Immunohistochemical results were evaluated by two pathol-
ogists (X.M.-G. and J.P.) by considering the percentage
and intensity of the staining. A histologic score was ob-
tained from each sample, and ranged from 0 (no immuno-
reaction) to 300 (maximum immunoreactivity). The score
was obtained by applying the following formula: Histoscore
 (1  percentage of cells with light staining)  (2 
percentage of cells with moderate staining) (3 percent-
age of cells with strong staining). Because each TMA in-
cluded two different tumor cylinders from each case, immu-
nohistochemical evaluation was performed after examining
both samples. The reliability of such scoring for interpreta-
tion of immunohistochemical staining in endometrial carci-
noma TMAs, and the reproducibility of TMA immunostain-
ing, with comparison of TMA results with those obtained
in sections from the corresponding paraffin blocks of 37
randomly selected cases, has been described previ-
ously.18,34,35
Statistical analysis was performed on a database (SPSS
for Windows version 11.5; SPSS, Inc.). The H score results
were compared using theMann-WhitneyU-test, the Student
t-test, the Kruskal-Wallis test, and analysis of variance when
applicable. Correlations between quantitative variables
were established using the Pearson and Spearman Rho
tests. P  0.05 was considered statistically significant.
Cell Lines, Culture Conditions, and Transfection
The Ishikawa 3-H-12 (IK) cell line was purchased from the
European Collection of Cell Cultures. KLE cells were a gift
from Dr. Palacios (CNIO). RL-95 and HEC-1-A cells were
a gift from Dr. Reventos (Hospital Vall d’Hebron, Barce-
lona, Spain). The IK cell line was grown in Dulbecco’s
modified Eagle’s medium (Sigma-Aldrich Corp.) supple-
mented with 10% fetal bovine serum (Invitrogen Corp.) and
1 mmol/L HEPES, 1 mmol/L sodium pyruvate, 2 mmol/L
L-glutamine, and 1% penicillin or streptomycin (all from
Sigma-Aldrich Corp.) at 37°C with saturating humidity and
5% CO2. When indicated, transfection plasmid constructs
were performed using lipofectamine 2000 reagent (Invitro-
gen Corp.) following the manufacturer’s instructions.Lentiviral Production and Infection
Oligonucleotides to produce plasmid-based shRNA were
cloned into the FSV vector using AgeI-BamHI restriction
sites. shRNA target sequences were as follows: KSR1 1.3,
5=-GCCTCCTTATTGCAGAAAGTT-3=; KSR1 2.6, 5=-GCACT-
GACAAAGAAGGCTCTT-3=; FADD, 5=-CATGGAACTCA-
GACGCATCT-3=; caspase 8, 5=-GAATCACAGACTTTGGA-
CAA-3=; FLIP, 5=-CCTCACCTTGTTTCGGACTA-3=; CK2, 5=-
TGGTTTCCCTCACATGCTCT-3=; and ITCH, 5=-CCAGAA-
GTCAAGGTCAATTA-3=. Lentiviral production was per-
formed as previously described.36
Colony Formation Assay and Assessment of
Apoptosis
Three days after infection, cells transduced with shRNA
for FSV or KSR1 were trypsinized and resuspended in
0.3% agar diluted in medium at a concentration of 3000
cells/mL. Cell colonies were evaluated after 15 days in
culture as previously described.34
BrdU Incorporation
For determination of proliferation, cells were incubated
with 3 ng/mL 5-bromodeoxyuridine (BrdU; Sigma-Aldrich
Corp.) for 20 minutes and fixed with 4% paraformalde-
hyde. After DNA denaturing with 2 mol/L HCl for 30 min-
utes and neutralization with 0.1 mol/L Na2B4O7 (pH 8.5)
for 2 minutes, cells were blocked in PBS solution contain-
ing 5% horse serum, 5% fetal bovine serum, 0.2% gly-
cine, and 0.1% Triton X-100 for 1 hour. Subsequently,
cells were subjected to indirect immunofluorescence with a
mouse anti-BrdU monoclonal antibody (DAKO Corp.) and
fluorescein isothiocyanate–conjugated anti-mouse second-
ary antibody (Molecular Probes, Inc., Eugene, OR). Nuclei
were counterstained with 5 g/mL Hoechst 33258, and
cells were visualized using an epifluorescence microscope
(Leica Microsystems GmbH, Wetzlar, Germany).
Western Blot Analysis
Western blot analysis was performed as previously de-
scribed.36 Densitometric quantification of Western blot
bands was performed using Quantity One software (Bio-
Rad Laboratories, Inc.).
Statistical Analysis
All data are given as mean (SE) of at least three indepen-
dent experiments. Differences between groups were de-
termined using the Student t-test. P  0.05 was consid-
ered statistically significant.
Results
KSR1 Is Overexpressed in Endometrial Carcinoma
In a cDNA array study, normal endometrium and ECC
cDNA expression profiles were compared. Supervised
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differences (unadjusted P value  0.001, and adjusted P
value  0.07) in expression of 155 genes between ECCs
and normal endometrium, including 62 up-regulated and
93 down-regulated genes in ECCs (Moreno-Bueno et al;
unpublished results). One of the up-regulated genes in
ECCs compared with normal tissue was KSR1 (accession
No. H88143). KSR1 was up-regulated 2.1-fold over nontu-
mor samples. This result was validated using semiquantita-
tive RT-PCR in the same series analyzed using cDNA arrays
and an independent series (series 1 or series 2) (Figure 1A).
Statistically significant differences were observed in KSR1
expression in both studied series.
To demonstrate that the increased KSR1 mRNA ex-
pression was associated with increased protein expres-
sion, immunohistochemistry for KSR1 was performed in
two TMAs constructed as described (see Materials and
Methods). To test the specificity of KSR1 antibody used
for immunohistochemistry, IK cells were infected with len-
tiviruses carrying the empty vector (FSV) or an FSV vector
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Figure 1. KSR1 expression is increased in endometrial carcinoma. A: Rep-
resentative gel (left) and quantification (right) of KSR1 mRNA expression in
two different series of normal endometrium (N; white bars) versus two
different series of endometrial carcinoma (EC1 and EC2; black bars) elicits
up-regulation of KSR1 mRNA in endometrial tumor samples. B: Endometrial
carcinoma TMA was constructed and immunostained (see Materials and
Methods). Representative images of KSR1 immunostaining of normal endo-
metrium (NE) and grade 1, 2, and 3 endometrial carcinomas (EC).containing two shRNAs targeting human KSR1 (KSR1 1.3and KSR1 2.6). Three days later, the ability of KSR1
shRNAs to cause its down-regulation was assessed us-
ing Western blot analysis. KSR1 2.6 but not KSR1 1.3
down-regulated KSR1 protein levels (see Supplemental
Figure S1A at http://ajp.amjpathol.org). To validate the
specificity of antibody used in TMAs, immunohistochem-
istry was performed on IK cells infected with lentiviruses
carrying shRNA 2.6 or the control vector using the same
protocol used for TMA staining. The antibody did not
stain IK cells infected with shRNA 2.6, but stained IK cells
infected with control vector (Figure S1B).
To investigate whether KSR1 was expressed in the
endometrium, expression of KSR1 was analyzed in a
TMA constructed from normal endometrium samples. In
normal endometrium, KSR1 was evaluated in all of the 80
cases included in the first TMA. KSR1 immunostaining
varied according to the phase of the menstrual cycle
(proliferative or secretory). KSR1 immunoexpression was
significantly higher in the secretory phase [mean (range)
histoscore, 3.11 (0 to 15)] than in the proliferative endo-
metrium [0.95 (0 to 5)] (P  0.0157). Staining was cyto-
plasmic. Afterward, expression of KSR1 was analyzed in
a TMA constructed from ECCs. Because endometrial car-
cinomas arise from epithelial endometrial cells, only ex-
pression of KSR1 in epithelial fraction was evaluated, in
normal and neoplastic tissue. However, stromal fraction
demonstrated low levels of KSR1 expression. Because of
cylinder losses caused by the immunostaining proce-
dure, KSR1 was evaluated in 134 of 157 cases. Overall,
KSR1 immunoexpression was significantly increased in
endometrial carcinoma compared with normal endome-
trium (Figure 1B). KSR1 was expressed in 122 cases
(91%). The KSR1 histoscore was 46.49 (0 to 182) in
endometrial carcinoma, and 2.22 in normal endometrium
(P  0.00001).
KSR1 expression was significantly increased in non-
endometrial carcinoma compared with endometrial car-
cinoma (P 0.01204). KSR1 expression was significantly
higher in grade 3 tumors than in grade 1 (P  0.01802)
and grade 2 (P  0.01057) tumors. No statistically sig-
nificant differences were observed when comparing
grade 1 and grade 2 endometrial carcinomas (P 
0.9011). However, no statistical significance was ob-
served in pathologic stage (P  0.7235). Moreover, no
significant relationship was observed between KSR1 ex-
pression and microsatellite instability (P  0.5599) or
mutations in KRAS (P  0.2967), CTNNB-1 (P  0.6457),
or PTEN (P  0.8390). Statistical analysis did not demon-
strate any significant correlation between KSR1 and FLIP
(P  0.15) in the tissue samples. The lack of correlation
between one protein involved in signaling pathways and a
putative target is a common observation in TMA studies.
Expression of FLIP, as of many other proteins, is controlled
by multiple signaling molecules or pathways such as NF-
B, PI3K/Akt, or CK2. These pathways are also altered in
endometrial carcinoma. Therefore, the total FLIP levels in
vivomay be the result of different signaling pathways. Thus,
it is difficult to correlate FLIP expression with the data ob-
tained in a single pathway or molecule.
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Figure 2. KSR1 knock-down inhibits proliferation and anchorage-independent cell growth. A: IK and KLE cells were infected with lentiviruses carrying the empty
vector (FSV), KSR1 shRNA or CK2 shRNAs, and after 3 days, were analyzed using BrdU incorporation. Quantification of BrdU-positive IK and KLE cells (bottom)
revealed that KSR1 shRNA cause a marked decrease in proliferating cells. Representative images of BrdU immunofluorescence in IK cells (top). B: IK cells were
infected with lentiviruses carrying the empty vector (FSV), KSR1 shRNA or CK2 shRNAs, and after 3 days, lysates were collected. Western blot analysis
demonstrated that both KSR1 shRNA and CK2 shRNA lead to marked down-regulation of CyclinD1, p-ERK. Membrane was reprobed using anti-KSR1 and
anti-CK2 antibody to ensure specific inhibition of KSR1 and CK2 and anti-tubulin and anti–pan-ERK to ensure equal protein loading. C: KSR1 shRNA causes
a dosage-dependent decrease in proliferating cells. IK cells were infected with increasing amounts of lentiviruses carrying the empty vector (FSV) or KSR1 shRNA.
Western blot analysis demonstrated dosage-dependent inhibition of KSR1 expression (left). Proliferating cells of matched IK cultures were analyzed using BrdU
incorporation. Quantification of BrdU-positive IK cells (left) and representative images of BrdU-stained cells (right). D: Soft agar experiment of IK cells infected
with increasing amounts of lentiviruses carrying the empty vector (FSV) or KSR1 shRNA caused a dosage-dependent colony formation. Representative image of
colonies in soft agar (left) and quantification of the number of colonies (middle) in FSV- or KSR1 shRNA–infected cells. Right, Higher magnification image
demonstrates that KSR1-infected cells are alive, although they do not form colonies. Error bars represent SE from three independent experiments. *P  0.05.
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Phenotype of ECCs
Increased proliferation and anchorage-independent cell
growth are two hallmarks of tumor phenotype. To ascertain
the role of KSR1 in endometrial carcinogenesis, two endo-
metrial cancer cell lines (IK and KLE) were infected with
viruses carrying KSR1 shRNA. The effects of KSR1 knock-
down on cell proliferation and anchorage-independent cell
growth were evaluated. Compared with cells infected with
the empty vector, KSR1 down-regulation caused a marked
decrease in BrdU incorporation, which suggests that KSR1
knock-down reduces cell proliferation (Figure 2A). As a
negative control, IK cells transduced with shRNA targeting
the CK2 subunit of the protein casein kinase 2 (CK2) were
used. CK2 is a ubiquitous, highly conserved, tetrameric
serine/threonine kinase composed of two regulatory sub-
units called CK2 and two catalytic subunits, which can be
two of either the subunits CK2 or CK2=.37–39 Increased
CK2 activity is associated with cell growth and proliferation,
and many types of tumors exhibit aberrant or increased
CK2 activity.40–42 Recently, it was demonstrated that CK2
knock-down reduces proliferation of ECCs34 Matched cul-
tures were lysed and analyzed at Western blotting with
antibodies to cyclin D1 and phosphorylated ERK. The
reduction of cell proliferation correlated with a marked
reduction of cyclin D1. ERK phosphorylation was also
decreased, indicating that KSR1 shRNA was efficiently
decreasing MAPK signaling (Figure 2B).
The intracellular amount of KSR1 is determinant for its
function on proliferation and oncogenic potential.9 To
demonstrate that high intracellular amounts of KSR1 are
determinant to promote proliferation of ECCs, a titration
experiment was performed in which IK cells were in-
fected with increasing dosages of lentiviruses carrying
KSR1 shRNA or the empty vector. Lentiviral titration re-
sulted in graded inhibition of endogenous KSR1 expres-
sion that consistently correlated with a decrease in BrdU
incorporation and mitotic index (Figure 2C). In contrast,
no effects were observed with increasing dosages of
lentiviruses carrying the empty vector.
Likewise, to investigate the role of KSR1 protein levels
on anchorage-independent growth properties, IK cells
were infected with increasing dosages of lentiviruses car-
rying KSR1 shRNAs, and after 3 days, cell cultures were
trypsinized and cultured in soft agar for 15 days, as
described previously. As shown in Figure 2D, KSR1
shRNA caused dosage-dependent inhibition of colonies,
which indicates that KSR1 levels regulate anchorage-
independent cell growth.
KSR1 Controls Sensitivity to TRAIL- and
aFas-Induced Cell Death in ECCs
Deregulation of apoptotic cell death is also a critical
event in development and progression of cancer. After it
was ascertained that KSR1 regulates both proliferation
and anchorage-independent cell growth, its potential role
in regulation of apoptosis was investigated. For this pur-
pose, IK cells were infected with virus carrying shRNAs toKSR1, and after 3 days, cells were treated with TRAIL or
aFas, and the apoptotic nuclei were visualized at
Hoechst staining. Treatment of IK cells with shRNA KSR1
2.6 alone resulted in a moderate increase in apoptotic
nuclei; however, addition of aFas or TRAIL resulted in a
dramatic increase in nuclei (Figure 3A). In contrast,
shRNA 1.3, which did not cause down-regulation of
KSR1, failed to sensitize IK cells to TRAIL-induced apop-
tosis. Moreover, TRAIL and aFas treatment caused activa-
tion of caspase 8 and caspase 3 in cells infected with
lentiviruses carrying KSR1 shRNA (Figure 3B). Similar re-
sults were obtained with other endometrial carcinoma cell
lines (see Supplemental Figure S2 at http://ajp.amjpathol.
org). These data demonstrate that KSR1 inhibition sensi-
tizes ECCs to apoptosis triggered by either TRAIL or aFas.
KSR1 Sensitization to TRAIL and aFas Requires
FLIP Down-Regulation and Expression of
Caspase 8 and FADD
High levels of FLIP are responsible for resistance to
TRAIL-induced apoptosis in ECCs.18 Because of the crit-
ical role of FLIP in death receptor apoptosis resistance in
ECCs, whether KSR1-mediated resistance to TRAIL and
aFas was caused by regulation of FLIP protein levels was
examined. IK cells were infected with lentiviruses carry-
ing KSR1 shRNA, and after 3 days, they were exposed to
TRAIL and aFas. Addition of either TRAIL or aFas to IK cells
infected with shRNA to KSR1 resulted in a dramatic de-
crease in FLIP protein levels (Figure 4A). Similar results
were obtained with other endometrial carcinoma cell lines
(see Supplemental Figure S3 at http://ajp.amjpathol.org).
To ascertain whether such FLIP down-regulation was the
cause of sensitization to TRAIL in KSR1-silenced ECCs, IK
cells were infected with a plasmid coding for a FLAG-
tagged mouse FLIP. After 3 or 4 days to enable FLIP ex-
pression, cells were treated with aFas. Apoptotic nuclei
were then visualized at Hoechst staining, and caspase pro-
cessing at Western blot analysis. Overexpression of FLIP
resulted in a dramatic reduction of apoptotic nuclei caused
by KSR1 shRNA plus either TRAIL or aFas (Figure 4B).
Consistent with this observation, FLIP overexpression inhib-
ited processing of caspases 8, 9, and 3 (Figure 4C).
To test whether KSR1 sensitization to TRAIL- and aFas-
induced apoptosis required a functional death-inducing
signaling complex, IK cells were co-infected with viruses
carrying KSR1, plus either caspase 8 or FADD shRNAs.
After 3 days, cells were treated with TRAIL. Hoechst stain-
ing revealed a decrease in the number of apoptotic nuclei in
cells infected with KSR1 shRNA plus either FADD or
caspase 8 shRNAs and exposed to TRAIL or aFas (Figure
4B). Accordingly, knock-down of FADD and caspase 8
blocked activation of all caspases analyzed at Western
blotting.
These results indicate that TRAIL sensitization to
apoptosis after KSR1 down-regulation requires adap-
tor protein FADD and initiator caspase 8 in the death-
inducing signaling complex to trigger an apoptotic re-
sponse (Figure 4D).
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Inhibition of FLIP Translation
Next investigated were the mechanisms by which
KSR1 regulates FLIP levels. First, whether FLIP levels
were transcriptionally regulated was assessed. For this
purpose, real-time PCR was performed on mRNA ex-
tracted from IK cells infected with lentiviruses carrying
KSR1 shRNA. Compared with cells carrying the empty
vector, cells carrying KSR1 shRNA did not demon-
strate a decrease in FLIP mRNA levels, even in IK cells
treated with TRAIL (Figure 5A). As a positive control of
FLIP down-regulation, FLIP mRNA from IK cells in-
fected with lentiviruses carrying FLIP shRNA or CK2
shRNA was analyzed.
FLIP levels are also regulated by ubiquitin-protea-
some–mediated degradation. The E3 ubiquitin ligase
ITCH is responsible for ubiquitin conjugation and subse-
quent degradation of FLIP through the proteasome.43–45
These observations enabled analysis of whether the
ubiquitin-proteasome system mediated FLIP down-regu-
lation. For this purpose, IK cells were co-infected with
KSR1 shRNA plus an shRNA targeting ubiquitin ligaseITCH expression and, thus, ubiquitin conjugation of FLIP.
ITCH inhibition did not prevent down-regulation of FLIP
(Figure 5B). To further exclude the role of the ubiquitin-
proteasome system in FLIP down-regulation, IK cells
were treated with the proteasome inhibitors MG-132,
bortezomib, or ALLN. Addition of any of the proteasome
inhibitors failed to inhibit reduction in FLIP protein caused
by TRAIL in cells with down-regulated KSR1 (Figure 5C).
Another suggested mechanism for FLIP degradation is
caspase processing. To investigate whether the de-
crease in FLIP levels was caused by caspase activation
after TRAIL treatment, IK cells infected with FSV or KSR1
shRNA were treated with TRAIL or TRAIL plus the broad-
caspase inhibitor BAF. Treatment of IK cells with BAF did
not inhibit FLIP down-regulation, although it efficiently
blocked processing of caspases 8, 9, and 3 and nuclei
with apoptotic features (Figure 5D).
Forced expression of FLAG-tagged mouse FLIP over-
came TRAIL-induced caspase processing and apoptosis
in KSR1 shRNA-infected IK cells. Expression of endoge-
nous FLIP levels was investigated in cells in which FLIP
was overexpressed. The FLIP antibody used in the pres-
Figure 3. Down-regulation of KSR1 sensitizes IK to
TRAIL- and aFas-induced apoptosis. A: Treatment of IK
with shRNA to KSR1 plus either TRAIL or aFas increases the
number of apoptotic nuclei and caspase activation. IK cells
were infected with lentiviruses carrying two different shR-
NAs targeting KSR1 (KSR1 1.3 and KSR1 2.6). After 3 days to
enable down-regulation of the protein, cells were treated
with 50 ng/mL TRAIL for 8 hours, and nuclei were visual-
ized at Hoechst staining. Results are given as percentage of
apoptotic nuclei compared with the total number of nuclei
(left). Representative images of Hoechst-stained IK cells
(right). Error bars represent SE from three independent
experiments. *P  0.05. B: KSR1 shRNA plus 50 ng/mL
TRAIL or aFas activate caspases 8 and 3. IK cells were
infected with lentiviruses carrying KSR1 shRNA 2.6. After 3
days to enable down-regulation of the protein, cells were
treated with 50 ng/mL TRAIL or aFas. After 8 hours, cells
were lysed, and protein extracts were analyzed at Western
blotting with antibodies to the indicated caspases. Mem-
branes were reprobed with tubulin to ensure equal
amounts of protein, and antibodies to KSR1 to check inhi-
bition by the specific shRNA. Blots are representative of
three experiments.ent study recognized human FLIP but not mouse FLIP,
nes were
th tubuli
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Western blot analysis of endogenous FLIP revealed that it
was down-regulated even when heterologous mouse
FLIP was overexpressed (Figure 6A). This indicates that
TRAIL-induced FLIP down-regulation by KSR1 shRNA
was not caused by a general or unspecific process of
degradation or down-regulation of gene expression re-
sulting from apoptotic cell death.
Apart from transcription and degradation, FLIP protein
levels may also be regulated by the mechanism of transla-
tion. To ascertain whether FLIP down-regulation was
caused by inhibition of FLIP translation, IK cells were treated
with TRAIL or with the inhibitor of translation cycloheximide
(CHX) for 8 hours in cells infected with either KSR1 shRNA
or FSV vector. Treatment with CHX led to a marked
decrease in FLIP protein levels in FSV-transfected
cells, which suggests that FLIP protein levels are main-
tained by continuous translation from its mRNA (Figure
6B). Addition of TRAIL to IK cells infected with KSR1
shRNA induced a level of decrease of eIF4E phosho-
rylation similar to that observed after CHX treatment,
which suggests that TRAIL-induced inhibition of trans-
Figure 4. KSR1 sensitization to TRAIL and aFas requires FLIP down-regulation
of TRAIL or aFas in cells infected with KSR1 shRNA, but not in FSV-infected ce
down-regulation of the protein, cells were left untreated (UN) or were treated w
at Western blotting with antibodies to FLIP. Membranes were reprobed with tu
and caspase 8 reduce the number of apoptotic nuclei caused by KSR1 shRNA pl
alone or with a FLAG-tagged FLIP expression plasmid (left graph) or either FA
or aFas were added to the culture. Nuclei exhibiting apoptotic features were v
quantification are given as the percentage of apoptotic nuclei compared with th
3. IK cells were infected with lentiviruses carrying a FLAG-tagged FLIP expression
cells were lysed, and protein extracts were analyzed at Western blotting with an
to ensure protein inhibition, and anti-FLAG to check heterologous FLIP express
NS, nonspecific bands. D: Down-regulation of caspase 8 or FADD inhibits activa
or together with FADD or caspase 8 shRNAs. After 3 days, 50 ng/mL TRAIL or a
analyzed at Western blotting with antibodies to the indicated caspases. Membra
protein inhibition by the specific shRNAs. Membranes were reprobed again wilation occurred in cells with silenced KSR1 (Figure 6B).Also assessed were the effects of caspase 8 and FADD
shRNAs on FLIP levels. Caspase 8 shRNA did not restore
FLIP levels, although it completely inhibited caspase acti-
vation and apoptosis. Conversely, FADD shRNA inhibited
FLIP down-regulation caused by TRAIL stimulation in KSR1-
silenced IK cells (Figure 6C). Such a differential effect of
caspase 8 and FADD shRNAs on FLIP protein levels
strongly correlated with the phosphorylation status of eIF4E.
FADD shRNA, but not caspase 8 shRNA, restored eIF4E
phosphorylation in cells treated with KSR1 shRNA plus
TRAIL. These data further support the inhibition of transla-
tion as a mechanism for FLIP down-regulation caused by
TRAIL in KSR1-silenced cells.
Re-Introduction of Heterologous KSR1 Restores
Apoptosis Resistance and Proliferation
To demonstrate the specific requirement of KSR1 in regu-
lation of FLIP protein levels and subsequent apoptotic re-
sponse to TRAIL, a heterologous mouse KSR1 cDNA that is
not targeted by human KSR1 shRNA was re-expressed. For
ase 8 and FADD expression. A: FLIP protein levels are decreased after addition
lls were infected with lentiviruses carrying shRNA KSR1. After 3 days to enable
g/mL TRAIL or aFas. After 8 hours, cells were lysed. Cell lysates were analyzed
ensure equal amounts of protein. B: FLIP overexpression or silencing of FADD
or aFas treatment. IK cells were infected with lentiviruses carrying KSR1 shRNA
spase 8 shRNAs (right graph). After 3 days, cells treated with 50 ng/mL TRAIL
using Hoechst staining, and counted after 8 hours. Results of apoptotic nuclei
mber of nuclei. C: FLIP overexpression inhibits activation of caspases 8, 9, and
. After 3 days, cells were stimulated with 50 ng/mL TRAIL or aFas. After 8 hours,
to the indicated caspases. Membranes were reprobed with anti-KSR1 antibodies
branes were reprobed again with tubulin to ensure equal amounts of protein.
aspases 8, 9, and 3. IK cells were infected with lentiviruses carrying KSR1 alone
added to the culture. After 8 hours, cells were lysed, and protein extracts were
reprobed with anti-FADD, anti–caspase 8, and anti-KSR1 antibodies to ensure
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AJP April 2011, Vol. 178, No. 4carrying KSR1 shRNA, and the day after infection they were
transfected with a plasmid-encoding mouse KSR1 cDNA.
After 2 days, cells were treated with TRAIL.
Re-introduction of mouse KSR1 cDNA in IK cells
caused marked inhibition of caspases 3, 8, and 9 pro-
cessing, indicating that KSR1 is a key element in deter-
mination of life-death signal after TRAIL stimulation (Fig-
ure 7A). Proper overexpression of KSR1 in this
experiment was monitored using antibodies to the FLAG
tag because the antibody used in this study was unable
to detect mouse KSR1.
More important, re-introduction of KSR1 caused
marked re-expression of FLIP protein (Figure 7B). This
result strongly supports the role of KSR1 in control of
endogenous FLIP protein levels and, thus, death recep-
tor–induced apoptosis.
Furthermore, overexpression of mouse KSR1 in-
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Ccreased the levels of ERK phosphorylation and re-stored the levels of cyclinD1 observed in normal cells
(Figure 7C), as well as BrdU incorporation (Figure 7D).
Discussion
To our knowledge, the present study provides the first
demonstration that KSR1 expression is elevated in endo-
metrial carcinoma. Moreover, it demonstrates that inhibi-
tion of KSR1 expression in ECCs causes a marked de-
crease in proliferation rates and anchorage-independent
cell growth. Further, KSR1 has a critical role in control of
sensitivity of ECCs to TRAIL-induced apoptosis and FLIP
protein translation.
Previous studies have demonstrated that KSR1 is nec-
essary to promote Ras-induced transformation in vivo and
in vitro. Moreover, pharmacologic inhibition of KSR1 ab-
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Figure 5. KSR1 shRNA does not alter FLIP tran-
scription and degradation. A: KSR1 shRNA did
not change the levels of FLIP mRNA. IK cells
were infected with lentiviruses carrying KSR1.
After 3 days, cells were stimulated with 50 ng/mL
TRAIL or aFas. mRNA was extracted and sub-
jected to reverse transcription. mRNA relative
levels were analyzed using real-time PCR. Re-
sults are given as relative mRNA levels compared
with untreated (UN) cells. B: The ubiquitin ligase
ITCH did not prevent FLIP down-regulation. IK
cells were infected with lentiviruses carrying
KSR1 alone or together with ITCH shRNA. After
3 days, 50 ng/mL TRAIL was added to the cul-
ture. After 8 hours, cells were lysed, and protein
extracts were analyzed at Western blotting with
antibodies to FLIP. Membranes were reprobed
with anti-ITCH antibodies to ensure protein in-
hibition by the specific shRNA. Membranes were
reprobed again with tubulin to ensure equal
amounts of protein. C: The ubiquitin-protea-
some system is not involved in FLIP down-reg-
ulation. IK cells were infected with lentiviruses
carrying KSR1. After 3 days, cells were treated
with 50 ng/mL TRAIL plus the indicated dosages
of the proteasome inhibitors MG-132, ALLN, or
bortezomib. After 8 hours, cells were lysed, and
protein extracts were analyzed at Western blot-
ting with antibodies to FLIP. Membranes were
reprobed with anti-ubiquitin antibodies to en-
sure effectiveness of the proteasome inhibitors.
Membranes were reprobed again with tubulin to
ensure equal amounts of protein. D: Caspases
are not responsible for FLIP down-regulation.
Right, IK cells were infected with lentiviruses
carrying KSR1. After 3 days, cells were treated
with 50 ng/mL TRAIL plus the caspase inhibitor
BAF. After 8 hours, cells were lysed, and protein
extracts were analyzed at Western blotting with
antibodies to FLIP. Membranes were reprobed
with anti-caspase antibodies to check caspase
inhibition by BAF. Membranes were reprobed
again with tubulin to ensure equal amounts of
protein. Left, Parallel cultures were Hoechst
stained, and the number of nuclei exhibiting
apoptotic features was scored. Results of apop-
totic nuclei quantification are given as the per-
centage of apoptotic nuclei compared with the
total number of nuclei. Error bars represent SE
from three independent experiments. *P  0.05.   FSV
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AJP April 2011, Vol. 178, No. 4This evidence supports an important role for KSR1 in
development of cancer. Data from cDNA and tissue mi-
croarray studies demonstrated that KSR1 expression is
elevated in endometrial carcinomas compared with nor-
mal endometrial tissue. These results provide the first
evidence of up-regulated expression of KSR1 in cancer
in human beings. Previous evidence demonstrated that
Raf/MEK/ERK signaling is altered in endometrial carcino-
genesis at different levels of the pathway such as muta-
Figure 6. Reduction of FLIP levels is posttranscriptional and FADD-depen
overexpression. IK cells were infected with lentiviruses carrying KSR1 shRNA
50 ng/mL TRAIL. After 8 hours, cells were lysed, and protein extracts were a
FLAG, and KSR1. Membranes were reprobed again with tubulin to ensure equ
phosphorylation and FLIP down-regulation in KSR1-silenced cells. IK cells we
panel). After 3 days, 50 ng/mL TRAIL or CHX was added to the culture. Ce
anti-tubulin. Densitometric quantification of FLIP expression in three differen
decrease. C: FADD shRNAs but not caspase 8 shRNAs prevent FLIP down-re
with lentiviruses carrying KSR1 alone or together with FADD or caspase 8 sh
cells were lysed, and protein extracts were analyzed at Western blotting with
FADD, caspase 8, and KSR-1 antibodies to check for protein knock-down. Me
Densitometric quantification of FLIP expression in three different indepen
*P  0.05.tions in KRAS or hypermethylation of RassF1A.46–48 Up-regulation of KSR1 as responsible for carcinogenesis
is compatible with the scaffolding function of KSR1 in
regulation of Raf/MEK/ERK signaling. The importance
of KSR1 concentration was evidenced by experiments
in which reintroduction of increasing amounts of KSR1 in
KSR1/ fibroblasts caused a dosage-dependent in-
crease in ERK signaling and transformation.9 Therefore, it
can be speculated that increased expression may have
an important role in development and progression of
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AJP April 2011, Vol. 178, No. 4To determine the role of KSR1 protein levels in endo-
metrial tumorigenesis, shRNA was used to inhibit endog-
enous KSR1 expression. The results showed that KSR1
inhibition blocked not only proliferation but also anchor-
age-independent cell growth. These results are in agree-
ment with previous reports that demonstrated a role for
KSR1 in control of cell cycle, proliferation, and oncogenic
potential of tumor cells,9,12,49 and further demonstrate
that KSR1 protein levels are important for the tumor phe-
notype of endometrial carcinoma.
Another hallmark of tumor cells is their ability to
evade apoptosis. KSR1 regulates apoptosis triggered
by anticancer agents such as cis-platin.50 KSR1 has
also been involved in modulation of apoptotic response
of B colonic epithelial cells to TNF,16,17 which sug-
gests a role for KSR1 in control of apoptosis triggered
by death receptors.
Apoptosis is a critical event in regulation of endome-
trial homeostasis. Previous studies have demonstrated
that proteins related to apoptosis regulation are deregu-
lated in endometrial carcinoma.33–35,51 Insofar as extrin-
sic or death receptor apoptosis, the results demonstrated
that ECCs exhibit high levels of FLIP, which confers
apoptotic resistance to both TRAIL and Fas ligand.18,19
Among death receptors and ligands, the ability to selec-
tively kill tumor cells has suggested that TRAIL may be a
promising anti-cancer agent.52,53 Although agonistic
TRAIL antibodies are under clinical trial for various types
of malignant diseases, some cancer cell types escape
apoptosis triggered by monotherapy with agonistic anti-
bodies. The decisions between life and death on TRAIL
stimulation can be regulated by several signaling path-
ways, depending on cellular context.54 Therefore, knowl-
edge about molecules involved in regulation of TRAIL
sensitivity to apoptosis may be helpful in development of
specific combination treatments. In this regard, the pres-
ent results represent the first evidence for a role of KSR1
in control of life/death decisions after TRAIL treatment.
Inhibition of KSR1 not only caused sensitization to TRAIL-
induced apoptosis, but also an increase in apoptosis
even in the absence of TRAIL or Fas. This feature in-
creases the potential of KSR1 inhibition as a tool for killing
endometrial tumor cells.
Figure 7. Re-introduction of heterologous KSR1 restores FLIP levels and
TRAIL resistance. A: Western blot analysis of caspase activation reveals that
re-introduction of KSR1 inhibits caspase activation. IK cells were infected
with lentiviruses carrying the empty vector (FSV) or KSR1 shRNA, and the day
after were transfected with pcDNA3 or pCDNA3-KSR1-FLAG. At 48 hours
after transfection, cells were treated with 50 ng/mL TRAIL for 8 hours. Cells
were lysed, and protein extracts were analyzed at Western blotting with
antibodies to the indicated caspases. Membranes were reprobed with anti-
tubulin to ensure equal protein amounts, anti-KSR1 to check inhibition by the
specific shRNA, and anti-FLAG to ensure heterologous KSR1 expression. B:
Analysis of lysates from same cultures at Western blotting demonstrate that
FLIP expression is re-sorted on re-introduction of KSR1. C: Hoechst staining
of parallel cultures demonstrated marked reduction in the number of nuclei
with apoptotic morphologic features. Results are given as the percentage of
apoptotic nuclei compared with the total number of nuclei. Representative
micrographs of Hoechst-stained cells. D: IK cells were infected with lentivi-
ruses carrying the empty vector (FSV) or KSR1 shRNA, and the day after were
transfected with pcDNA3 or pCDNA3-KSR1-FLAG. Cell lysates were collected
and analyzed at Western blotting with anti-cyclinD1 or anti–p-ERK antibod-UN TR UN TR
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AJP April 2011, Vol. 178, No. 4The molecular mechanisms by which KSR1 controls
FLIP protein levels were further elucidated. FLIP is con-
stitutively or highly expressed in some tumors,55–59 and
its expression can be regulated at both the transcriptional
and posttranscriptional levels. It was recently demon-
strated that CK2 regulates FLIP levels by modulating its
transcription and proteasome-mediated degradation.19
In contrast, the present study demonstrated that KSR1
did not modify FLIP mRNA levels in either the presence or
absence of TRAIL, which suggests posttranscriptional
regulation. At the posttranscriptional level, FLIP can be
regulated by both translation and degradation. An in-
creasing number of reports demonstrate that FLIP protein
is primarily degraded by the ubiquitin-proteasome sys-
tem. The E3 ubiquitin ligase ITCH mediates proteasome
degradation of FLIP.45 The present study demonstrated
TRAIL-triggered FLIP down-regulation even in cells in-
fected with ITCH shRNA. These data do not exclude the
possibility that other ubiquitin ligases may function to
ubiquitylate FLIP in endometrial cells. Nonetheless, pro-
teasome inhibitors did not block FLIP reduction in KSR1-
silenced cells, which suggests that KSR1 does not reg-
ulate proteasomal degradation of FLIP.
Another explanation for FLIP down-regulation is that it
results from a general process of protein degradation
associated with degeneration of a dying cell. However,
this possibility was excluded after the observation that
FLIP down-regulation occurred even in cells in which
heterologous mouse FLIP was overexpressed. In this set-
ting, activation of caspases and apoptosis was inhibited;
however, endogenous FLIP protein was still down-regu-
lated. This result demonstrates that endogenous FLIP
protein levels are tightly regulated.
It was demonstrated that CHX, an inhibitor of transla-
tion, caused down-regulation of FLIP similar to that ob-
served with treatment with TRAIL plus KSR1 shRNA. In-
creasing evidence points to regulation of translation as a
mechanism involved in regulation of proteins of the apop-
totic machinery. Recent findings have demonstrated that
some chemotherapeutic drugs such as sorafenib inhibit
Mcl-1 or FLIP protein translation, likely by regulating
eIF4E phosphorylation60. Moreover, in other cell types,
FLIP-S translation is critical in determination of TRAIL
sensitivity.61–63 In line with these results, addition of
TRAIL to ECCs with KSR1 shRNA caused inhibition of
eIF4E phosphorylation to the same extent as that ob-
served with CHX treatment.
Inhibition of the ERK pathway controls TRAIL-in-
duced apoptosis.64–66 Because KSR1 is a critical reg-
ulator of ERK/MAPK signaling, it is logical to think that
inhibition of KSR1 may sensitize ECCs to TRAIL by
inhibition of ERK activation. However, previous studies
have demonstrated that inhibition of ERK/MAPK signal-
ing is not involved in sensitization of ECCS to apoptosis
induced by TRAIL.67
TRAIL engagement of DR4 and DR5 receptors leads to
recruitment of the adaptor protein FADD, which serves as
a docking protein for both caspase 8 and FLIP. There-
fore, it is logical that both FADD and caspase 8 shRNA
overcame KSR1 sensitization to TRAIL. However, the ef-
fects of these two shRNAs on FLIP protein levels werecompletely different. Caspase 8 down-regulation did not
prevent a decrease in FLIP, whereas FADD knock-down
restored FLIP levels to those observed in untreated cells.
Caspase 8 inhibits apoptosis because it impairs down-
stream caspase activation; however, it does not block
binding of FADD on TRAIL stimulation. This result and
those obtained with the caspase inhibitor BAF make it
unlikely that down-regulation of FLIP is caused by
caspase degradation, as observed in other cell
types.30,68,69 In contrast, inhibition of FADD should inhibit
all downstream signaling after TRAIL receptor signaling.
Then, if it is postulated that KSR1 modulation of FLIP
translation depends on ligand binding, eIF4E dephos-
phorylation and subsequent FLIP down-regulation should
not occur in the absence of FADD. Addition of TRAIL in
cells co-infected with KSR1 and FADD shRNAs did not
cause dephosphorylation of eIF4E, and consistently, FLIP
protein levels were maintained at normal levels. This re-
sult strongly supports TRAIL-induced inhibition of FLIP
translation in the absence of KSR1.
Furthermore, it is believed that complementation ex-
periments using mouse KSR1 cDNA provided strong
evidence of the direct effects of KSR1 expression on
proliferation and apoptosis of ECCs. Re-introduction of
KSR1 overcame sensitization to TRAIL in cells with
silenced endogenous KSR1 expression and, more im-
portant, restored FLIP levels to those observed in con-
trol cells, demonstrating a role for KSR1 in control of
FLIP protein.
Recently it was demonstrated that the protein kinase
CK2 has an important role in mediating resistance of
ECCs to TRAIL and aFas-induced cell death.19 In that
study,19 pharmacologic inhibition of CK2 or knock-down
of the CK2 regulatory subunit sensitized ECCs to apop-
tosis triggered by either TRAIL or aFas. In contrast, re-
cent findings demonstrated that KSR1 interacts with
CK2.70 Taking into account these results and the role of
KSR1 and CK2 in apoptosis resistance, it is tempting to
speculate that both proteins can interact and cooperate
in control of FLIP. However, the mechanisms by which
CK2 and KSR1 control FLIP levels are largely different.
First, CK2 controlled transcription and degradation of
FLIP, whereas KSR1 regulated its translation. Second,
CK2 shRNA caused marked down-regulation of FLIP in
the absence of TRAIL, whereas KSR1 shRNA mediated
down-regulation of FLIP requires TRAIL treatment. Third,
it has been suggested that KSR1 acts as a functional
kinase.14,16,71,72 However, whether it possesses intrinsi-
cally kinase activity in mammals is still controversial, and
further investigations will be required to address this
point. Future work will examine whether CK2/KSR1 inter-
actions and the putative kinase activity of KSR1 are re-
quired for maintenance of FLIP levels and, ultimately,
TRAIL sensitivity.
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